Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma
Mayo Clinic
Mayo Clinic
University of California, San Diego
Institut Cancerologie de l'Ouest
Boehringer Ingelheim
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Wake Forest University Health Sciences
Thomas Jefferson University
University of Wisconsin, Madison
University of California, Davis
St. Joseph's Hospital and Medical Center, Phoenix
Thomas Jefferson University
Thomas Jefferson University
Thomas Jefferson University
NYU Langone Health
National Cancer Institute (NCI)
University of Oxford
Medical University of South Carolina
Medical College of Wisconsin
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Dartmouth-Hitchcock Medical Center
University of Pittsburgh
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
University of Chicago
University of Rochester
Duke University
Istari Oncology, Inc.
Stanford University
Translational Drug Development
Northwestern University
TuHURA Biosciences, Inc.
OHSU Knight Cancer Institute
University of Arkansas
National Cancer Institute (NCI)
Wake Forest University Health Sciences
Boston Scientific Corporation
Daiichi Sankyo
Universitaire Ziekenhuizen KU Leuven
University of Texas Southwestern Medical Center
Emory University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Medical University of South Carolina
NYU Langone Health
H. Lee Moffitt Cancer Center and Research Institute
Translational Research in Oncology
Applied Biology, Inc.
Northwestern University
Khyber Medical University Peshawar
Masonic Cancer Center, University of Minnesota
Northwestern University